ABSTRACT Eight patients with chronic severe asthma, poorly controlled by conventional doses of inhaled bronchodilator, were treated with high-dose inhaled terbutaline (4 mg four times daily), via either wet nebulisation of terbutaline respirator solution, or by tube-spacer aerosol, using cannisters delivering 1 mg terbutaline per metered dose. All patients improved objectively and subjectively on these higher dosage regimens during both day and night. A trial of high-dose inhaled beta2 sympathomimetic therapy should be considered in any patient with chronic severe asthma who fails to obtain benefit from standard doses of inhaled bronchodilator.
Patients with chronic severe asthma often respond poorly to inhaled bronchodilators in conventional dosage. Such patients are usually very disabled, require frequent hospital admissions, and are commonly prescribed long-term oral corticosteroids. Domiciliary high-dose inhaled bronchodilator therapy, delivered by wet nebulisation, may improve some patients with chronic asthma sufficiently for oral steroids to be discontinued.' However, the air compressors necessary for the domiciliary nebulisation of bronchodilator are expensive and inconvenient. We decided, therefore, to compare the efficacy of high-dose bronchodilator therapy delivered by wet nebulisation and by a new aerosol device, the tube-spacer.2 The tube-spacer was chosen because it achieves higher penetration of aerosol into the lung than does conventional aerosol,3 and also because it may be more effective than conventional aerosol in the management of some patients with asthma.4-6 The tube-spacer is cheaper and more convenient than the wet nebuliser.
Methods
Eight patients (four male and four female) with chronic severe asthma participated in the study. Mean first second forced expired volume (FEV1) was 0 83 I BTPS (range 0I5-1V61 BTPS). Average age was 60 years (range 53-67 years). Before the study started, diurnal variation of peak expiratory flow rate (PEFR) was documented by home-monitoring of PEFR, using the mini-Wright peak flow meter.7 All patients showed 15% or more diurnal variation in PEFR either spontaneously or after bronchodilator. Four patients were receiving oral prednisolone (dose range 10-15 mg per day). All patients were being treated with inhaled salbutamol 200-400 ,ug High-dosc inh/aled tcehbltalilie in thc management of l'chtroic seivre asthma
The trial consisted of thl-ee phases, each lastinig two weeks, aind was of "opent" design. The patients were inIstructed in the use of the mini-Wi-ighit peak flow meter, and asked to record PEFR (bcst of three attempts) on waking and on reti-ing to bed. (This measuremilent was made before bronichiodilator therapy, since the study was designed to examine the prophylactic efTect of bronchodilator on airflow obstruction and symptoms rather thani maximal bronchiodilator effect.) Patients were asked to record a 'symptom score" (table) DuLring phase I (two-week "ruLn-in11" period) patients took their usuial medicationi, and recordedi PEFR and symptom scores. The second and third phases were of randomised crossover design betweeni wet nebulisation and tube-spacer delivery methods for terbutaline. Terbutaline 4 mg (0 4 ml terbutaline respirator solution in I ml sterile water) was inhaled four times daily from the wet nebulisel using a RTU4 Medic Aid Compressor which delivers aboLit 16o,, of the dose placed within the nebuliser; approximately 80",, of the particles delivered are less than 7 ,km diameter and 60," of the particles are within the 1-4 )um range. The saimie dose of terbutaline (4 mg four times daily) was inhaled from a tube-spacer. PEFR and symptom scores were recorded as before.
DLuring plaises 2 aind 3, usuial bronchiodilatoaerosol theraipy was omitted, bItt no other-chdlinge was made in treatment.
Patients were asked to recor-d aniy side-effects aiid were informed that some of these could be irrita- Tlhere was n1o overaill statistically significanit differenice between nebuliser-anid tube-spacer methods of delivery, but onie patienit (patienit 2) showed (a conisider-ably better responise to inhaled terbutaline ila nlebuliser thanl via tube-spacer. Nighit ainid day symilptom scores were significantly better during treaitment phases with high-dose terbutaline vial eitlher-nebuliser or1 tube-spacer, thani durillg the cointrol period (p < 0 02). Tlhere was nlo signilficaint diffeerence between nebuliser or1 tube-spacer-delive-ry methods. Again, patient 2 showed greater-improvcment in syniptom scor-es oin nebuilised terbUtaline t hani on tuibe-spacer delivery of terbLitali1ne. Night symptom scores tended to improve more than daytime scores during therapy with high dose terbutaline via both nebuliser and tube-spacer. No patient reported any side-effects while on high dose terbutaline therapy.
Discussion
This study confirms the observations of others' 8 that patients with chronic asthma may be undertreated with conventional doses of inhaled bronchodilator. Our findings that the tube-spacer delivery method was as effective in improving symptoms and PEFR as wet nebulisation in seven out of the eight patients are important, since the tube-spacer is considerably cheaper and more convenient for domiciliary use than the wet nebuliser. We cannot be certain whether the improvement in each patient was attributable to the larger dose of bronchodilator delivered, the method of delivery or a combination of both factors. Although the tube-spacer allows greater delivery of bronchodilator to the bronchial tree than does conventional pressurised aerosol,3 an equivalent dose of bronchodilator delivered by pressurised aerosol or Rotahaler might Prior, Nowell, Cochrane be as effective as nebuliser or tube-spacer.
A feature of this study was the degree of improvement in nocturnal symptoms in patients on high dose terbutaline. The duration of bronchodilator activity is related to the inhaled dose.9 A higher dose of inhaled bronchodilator at bed time should be more effective in the prophylaxis of nocturnal bronchoconstriction and symptoms than a standard dose. Better daytime control of asthma might also improve nocturnal symptoms. Raising bed time PEFR by better daytime control of asthma could therefore exert a prophylactic effect on nocturnal cough and wheeze.
At present, the only convenient delivery method for high-dose inhaled bronchodilator therapy is the pressure-driven nebuliser employing respirator solutions. Simpler and cheaper high dose bronchodilator delivery systems (high-dose inhaler or Rotahaler) would be desirable. However, many physicians are still reluctant to use10 and drug companies reluctant to advise higher doses of inhaled bronchodilator when conventional doses do not achieve adequate control of symptoms. This may reflect the epidemic of asthma deaths in 1960s associated with the apparent excessive use of inhalers." Provided that patients on high-dose inhaled beta2 stimulants are instructed to obtain immediate medical advice should their asthma suddenly deteriorate, such therapy appears to be safe, and the lack of side-effects or toxicity in our patients on high dose inhaled terbutaline supports this view.
Patients with chronic severe asthma should be given a trial of high-dose inhaled bronchodilator therapy. While wet nebulisation is the only practical delivery method available at present, our study has shown that cheaper and more convenient methods of high-dose bronchodilator aerosol delivery can be just as effective as wet nebulisation.
